Back to top
more

Masimo (MASI)

(Real Time Quote from BATS)

$107.20 USD

107.20
53,353

-0.89 (-0.82%)

Updated Jul 30, 2024 11:17 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Masimo's (MASI) iSirona to Boost Hospital Automation Platform

by Zacks Equity Research

Masimo's (MASI) iSirona helps in efficient workflow in hospitals by providing continuous connectivity, thereby helping clinicians to improve patient outcomes.

    Masimo (MASI) Reports Encouraging 2020 Preliminary Results

    by Zacks Equity Research

    Per the preliminary announcement, Masimo (MASI) projects 2020 product revenues to improve.

      Debanjana Dey headshot

      Digital Health M&As Gain Precedence in the New Normal

      by Debanjana Dey

      The booming digital health space has been witnessing significant M&A activities amid the pandemic.

      Masimo's (MASI) Telehealth Solution Helps in COVID-19 Crisis

      by Zacks Equity Research

      Masimo (MASI) is lending support to Renown Health through Masimo SafetyNet in order to manage the COVID-19 surge.

      Masimo (MASI) Releases Favorable Findings on Pulse Oximetry

      by Zacks Equity Research

      Researchers on probe discover that the use of Masimo's (MASI) SpHb was related to the lower rate of postoperative transfusion, minimal duration of ICU stay and other better outcomes.

      Masimo (MASI) Earnings and Revenues Beat Estimates in Q3

      by Zacks Equity Research

      Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q3.

      Masimo (MASI) Q3 Earnings and Revenues Top Estimates

      by Zacks Equity Research

      Masimo (MASI) delivered earnings and revenue surprises of 42.86% and 1.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

      ABIOMED (ABMD) to Report Q2 Earnings: What's in the Offing?

      by Zacks Equity Research

      The full commercial launch of Impella 5.5 in May is expected to have contributed to ABIOMED's (ABMD) fiscal second-quarter results

      Quidel (QDEL) to Report Q3 Earnings: What's in the Offing?

      by Zacks Equity Research

      Quidel (QDEL) is likely to have witnessed an uptick in rapid immunoassay revenues in Q3.

      DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

      by Zacks Equity Research

      Solid performance by the net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in the third quarter.

      Varian (VAR) to Report Q4 Earnings: What's in the Offing?

      by Zacks Equity Research

      Varian's (VAR) solid Oncology platform is expected to have driven fiscal fourth-quarter performance.

        Cerner (CERN) to Report Q3 Earnings: What's in the Offing?

        by Zacks Equity Research

        Cerner's (CERN) third-quarter results are likely to reflect solid show by Subscriptions and Managed Services segments.

          PerkinElmer (PKI) to Post Q3 Earnings: What's in the Offing?

          by Zacks Equity Research

          PerkinElmer's (PKI) third-quarter results are likely to reflect strong performance at Diagnostics segment.

            DexCom (DXCM) to Report Q3 Earnings: What's in the Cards?

            by Zacks Equity Research

            DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.

            Masimo (MASI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

            by Zacks Equity Research

            Masimo (MASI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

            Aphria (APHA) to Report Q1 Earnings: What's in the Offing?

            by Zacks Equity Research

            Aphria's (APHA) fiscal first-quarter results are likely to reflect higher sales from medical and adult-use cannabis products.

            Why Masimo (MASI) is Poised to Beat Earnings Estimates Again

            by Zacks Equity Research

            Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

            What's in Store for Intuitive Surgical's (ISRG) Q3 Earnings?

            by Zacks Equity Research

            Intuitive Surgical's (ISRG) third-quarter earnings are likely to reflect weaker-than-expected performance at Instruments & Accessories segment.

            Sriparna Ghosal headshot

            3 Large-Cap MedTech Growth Stocks to Buy Amid the Pandemic

            by Sriparna Ghosal

            Let's take a look at three large-cap MedTech stocks that are currently flourishing on the back of a number of positive developments.

            Masimo Unveils New Wearable Wireless Continuous Thermometer

            by Zacks Equity Research

            Masimo's (MASI) wearable wireless continuous thermometer offers consumers hassle-free continuous body temperature measurements, thereby eliminating the need for manual measurements.

              Masimo's (MASI) Rad-G Pulse Oximeter Receives FDA Clearance

              by Zacks Equity Research

              Masimo's (MASI) Rad-G Pulse Oximeter receives FDA clearance, thereby allowing clinicians to access the most accurate and reliable pulse oximetry monitoring technologies.

                Masimo's (MASI) O3 Regional Oximetry Attains FDA Approval

                by Zacks Equity Research

                Masimo's (MASI) O3 Regional Oximetry's FDA clearance can help clinicians offer quick and accurate care

                Masimo (MASI) Down 0.3% Since Last Earnings Report: Can It Rebound?

                by Zacks Equity Research

                Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                Masimo Releases Favorable Study Results on Pulse Oximetry

                by Zacks Equity Research

                The pulse oximetry study result should be a major breakthrough for Masimo (MASI) to capture the neonatal patient care market.

                Masimo PVi Gets FDA Approval to Measure Fluid Responsiveness

                by Zacks Equity Research

                The FDA approval of Masimo's (MASI) PVi system will enable patient safety.